Literature DB >> 30008871

MicroRNA-218 inhibits the migration, epithelial-mesenchymal transition and cancer stem cell properties of prostate cancer cells.

Bing Guan1, Lijun Mu1, Linlin Zhang1, Ke Wang1, Juanhua Tian1, Shan Xu1, Xinyang Wang1, Dalin He1, Yuefeng Du1.   

Abstract

MicroRNA (miRNA) is a class of non-coding single-stranded RNA, able to regulate tumor-associated genes via binding the 3'-UTR of the target gene mRNA. Previous publications have demonstrated that miRNA-218 (miR-218) acts as a tumor-suppressive miRNA in various types of human cancer, including prostate cancer (PCa). However, the role of miR-218 in regulating PCa cell stemness and epithelial-mesenchymal transition remains unknown and requires further research. In the present study, it is demonstrated that miR-218 was downregulated in 2 PCa cell lines and could suppress cell migration, EMT and the exhibition of cancer stem cell-like properties. The expression of GLI family zinc finger 1 (Gli1) was inhibited by miR-218 overexpression, suggesting miR-218-suppression of Gli1 as a potential mechanism for the tumor-suppressive effect of miR-218. Overall, the results indicate that miR-218 served a critical role in the inhibition of PCa development. This may provide new insight for elucidating the mechanisms of PCa oncogenesis and suggests that miR-218 may be a novel therapeutic target for PCa.

Entities:  

Keywords:  cancer stem cell properties; epithelial-mesenchymal transition; microRNA-218; migration; prostate cancer

Year:  2018        PMID: 30008871      PMCID: PMC6036488          DOI: 10.3892/ol.2018.8877

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  How microRNAs control cell division, differentiation and death.

Authors:  Eric A Miska
Journal:  Curr Opin Genet Dev       Date:  2005-10       Impact factor: 5.578

Review 3.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 4.  Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression.

Authors:  Thomas Brabletz; Andreas Jung; Simone Spaderna; Falk Hlubek; Thomas Kirchner
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

Review 5.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.

Authors:  Naoko Takebe; Pamela J Harris; Ronald Q Warren; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2010-12-14       Impact factor: 66.675

6.  microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression.

Authors:  Guangye Han; Maochuan Fan; Xinjun Zhang
Journal:  Biochem Biophys Res Commun       Date:  2014-12-13       Impact factor: 3.575

7.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

Review 8.  Advances in androgen receptor targeted therapy for prostate cancer.

Authors:  Alia Ahmed; Shadan Ali; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2014-03       Impact factor: 6.384

9.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.

Authors:  Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun-Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F Wiggins; Andreas G Bader; Randy Fagin; David Brown; Dean G Tang
Journal:  Nat Med       Date:  2011-01-16       Impact factor: 53.440

10.  miR-218 Inhibits Proliferation, Migration, and EMT of Gastric Cancer Cells by Targeting WASF3.

Authors:  Guojun Wang; Yang Fu; Guanghui Liu; Yanwei Ye; Xiefu Zhang
Journal:  Oncol Res       Date:  2016-09-16       Impact factor: 5.574

View more
  6 in total

1.  The Effect of hsa-miR-451b Knockdown on Biological Functions of Gastric Cancer Stem-Like Cells.

Authors:  Diba Borzabadi Farahani; Hassan Akrami; Behrouz Moradi; Kiumars Mehdizadeh; Mohammad Reza Fattahi
Journal:  Biochem Genet       Date:  2021-03-16       Impact factor: 1.890

Review 2.  Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies.

Authors:  Abdul Q Khan; Eiman I Ahmed; Noor R Elareer; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cells       Date:  2019-08-05       Impact factor: 6.600

3.  α-E-Catenin (CTNNA1) Inhibits Cell Proliferation, Invasion and EMT of Bladder Cancer.

Authors:  Qiang Chi; Hui Xu; Dianbin Song; Zhiyong Wang; Zemin Wang; Guang Ma
Journal:  Cancer Manag Res       Date:  2020-12-14       Impact factor: 3.989

Review 4.  EMT-associated microRNAs and their roles in cancer stemness and drug resistance.

Authors:  Guangtao Pan; Yuhan Liu; Luorui Shang; Fangyuan Zhou; Shenglan Yang
Journal:  Cancer Commun (Lond)       Date:  2021-01-27

5.  LncRNA SOX2-OT regulates AKT/ERK and SOX2/GLI-1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases.

Authors:  Abril Marcela Herrera-Solorio; Irlanda Peralta-Arrieta; Leonel Armas López; Nallely Hernández-Cigala; Criselda Mendoza Milla; Blanca Ortiz Quintero; Rodrigo Catalán Cárdenas; Priscila Pineda Villegas; Evelyn Rodríguez Villanueva; Cynthia G Trejo Iriarte; Joaquín Zúñiga; Oscar Arrieta; Federico Ávila-Moreno
Journal:  Mol Oncol       Date:  2020-12-25       Impact factor: 6.603

6.  Dicer-mediated miR-200b expression contributes to cell migratory/invasive abilities and cancer stem cells properties of breast cancer cells.

Authors:  Tung-Wei Hsu; Hsin-An Chen; Po-Hsiang Liao; Yen-Hao Su; Ching-Feng Chiu; Chih-Yang Huang; Yu-Jung Lin; Chih-Chiang Hung; Ming-Hsin Yeh; Shian-Ying Sung; Chih-Ming Su
Journal:  Aging (Albany NY)       Date:  2022-08-08       Impact factor: 5.955

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.